Microcap Ledger

Tickers · $EDIT

Editas Medicine, Inc. $EDIT

By Microcap Ledger desk · CIK 0001650664

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Global Select Market
Sector
Biological Products, (No Diagnostic Substances)
Headquarters
Cambridge, MA
Fiscal year end
December 31
Shares outstanding
153,580,035 [10-Q 2026-08-05]
as of 2026-07-31

Sources: [10-K 2026-03-09]

What the company doesAI summary of filing

Editas Medicine is a preclinical-stage gene editing company that develops CRISPR-based genomic medicines to treat serious diseases. The company has not generated revenue from product sales and is focused on in vivo gene editing programs, with its lead candidate EDIT-401 in preclinical development for treating high cholesterol by upregulating the LDL receptor gene. Editas makes money through licensing its CRISPR technology to partners such as Vertex Pharmaceuticals and Bristol Myers Squibb, receiving upfront payments, milestone payments, and royalties on future sales. The company operates a proprietary gene editing platform based on CRISPR/Cas9 and CRISPR/Cas12a enzymes and pursues both internal development and in-licensing of complementary technologies to advance its pipeline. [10-K 2026-03-09]

Segments: EDIT-401 (Cardiovascular/Hyperlipidemia), Hemoglobinopathies (ex vivo program), In vivo HSC editing (Hemoglobinopathies), Other Cells/Tissues

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$14.72M−$43.21M −$52.63M$181.81M[10-Q 2026-08-05]
FY ended Dec 2025$40.52M−$160.06M −$165.24M$146.65M[10-K 2026-03-09]
FY ended Dec 2024$32.31M−$237.09M −$210.28M$131.54M[10-K 2026-03-09]
Quarterly cash burn
−$26.31M
Cash runway Estimate
~20.7 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-10-3082,548,099[10-Q 2024-11-04]
2025-02-2882,976,284[10-K 2025-03-05]
2025-05-0783,712,859[10-Q 2025-05-12]
2025-08-0789,920,164[10-Q 2025-08-12]
2025-10-3197,618,660[10-Q 2025-11-10]
2026-02-2797,871,999[10-K 2026-03-09]
2026-04-2997,906,282[10-Q 2026-05-05]
2026-07-31153,580,035[10-Q 2026-08-05]
Shelf registration
S-3 filed 2026-08-31; declared effective 2026-09-08 [S-3 2026-08-31]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-09-03Burkly Lindasell709$3.04[4 2026-09-04]
2026-09-03Parison Amysell453$3.04[4 2026-09-04]
2026-09-03O'Neill Gilmore Neilsell5,124$3.04[4 2026-09-04]
2026-08-03Parison Amysell678$2.58[4 2026-08-05]
2026-07-28Burkly Lindasell4,928$2.67[4 2026-07-29]

Catalysts and calendar

Recent filings and releases
DateTypeTitle
2026-10-088-KRegulation FD disclosure; Other events
2026-08-31S-3Registration statement
2026-08-1413GBeneficial ownership report (5%+ holder)
2026-08-0510-QQuarterly report
2026-08-058-KResults of operations; Director or officer change
2026-07-2913G/ABeneficial ownership report (5%+ holder)
2026-06-188-KShareholder vote results
2026-06-0313GBeneficial ownership report (5%+ holder)
2026-06-0313GBeneficial ownership report (5%+ holder)
2026-06-0213GBeneficial ownership report (5%+ holder)
2026-05-26424B5Prospectus or prospectus supplement
2026-05-268-KMaterial agreement entered; Other events

Facts as of . Small caps move fast; check the latest filings.